ESR1 and breast cancer: In fact, it has been observed that a significant number of estradiol-sensitive (ERα-positive) breast cancer cases co-express GPER-1 (78), which is associated with worse prognosis and diminished survival of patients, even in those patients treated with tamoxifen (78, 79).